TheraRadar
← Back
Data updated: Jul 17, 2026

NEXAIR LLC

Pharma
Pharmaceuticals

NEXAIR LLC is a pharmaceutical company with 3 FDA-approved products.

2013
Since
3
Drugs
-
Trials
7
New Drugs (2yr)
Modality:
3 Small Molecules

NEXAIR LLC's Key Drugs

NEXAIR LLC's core commercial portfolio centers on CARBON DIOXIDE, USP, HELIUM, USP, MEDICAL AIR, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013
HELIUM, USP
Respiratory
Approved 2013
MEDICAL AIR, USP
Respiratory
Approved 2013

NEXAIR LLC's Recent FDA Approvals

NEXAIR LLC secured 7 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

NEXAIR LLC's Therapeutic Areas

Disease areas where NEXAIR LLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

NEXAIR LLC Pipeline Snapshot

Active clinical trials for NEXAIR LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling